New drug cocktail aims to tackle tough pancreatic cancer

NCT ID NCT07685470

Not yet recruiting Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This study tests a new drug called becotatugvedotin combined with the chemotherapy gemcitabine for people with advanced pancreatic cancer that has not responded to first-line treatment. The trial has two phases: first, to find the safest dose of the new drug, and second, to see how well the combination works at controlling the cancer. About 30 participants will receive the treatment until their disease worsens or side effects become too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: becotatugvedotin plus gemcitabine
What this could lead to: If successful, this combination could offer a new treatment option for people with advanced pancreatic cancer who have run out of standard therapies.
What could go wrong: This is an early-phase study with only 30 participants, so results may not apply to everyone. The drug combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA (PDAC) SECOND LINE TREATMENT

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.